Why the study?
Cardiotoxicity related to 5-FU causes significant morbidity and mortality, creating a clinical dilemma regarding whether patients with major cardiac side effects can be safely rechallenged.
Can a patient with prior 5-FU-induced ventricular fibrillation be safely rechallenged with 5-FU using prophylactic antianginal therapy?
Can a patient with prior 5-FU-induced ventricular fibrillation be safely rechallenged with 5-FU using prophylactic antianginal therapy?
5-FU rechallenge may be feasible even after severe cardiotoxicity (ventricular fibrillation) when utilizing a multidisciplinary approach and prophylactic antianginal therapy.
Answers are grounded in this paper and cite their sources.
May inform individualized 5-FU rechallenge decisions with prophylaxis; hypothesis-generating and requires prospective trials before practice change.
BACKGROUND 5-Fluorouracil (5-FU) is a widely used intravenous chemotherapy agent that is highly effective in the treatment of a variety of solid malignancies. Cardiotoxicity related to 5-FU is a complex clinical entity associated with significant morbidity and mortality. Whether a patient who experienced a major cardiac side effect from 5-FU can be safely rechallenged with this drug is a clinical dilemma. CASE REPORT We present the case of a patient with stage III colorectal adenocarcinoma who experienced ventricular fibrillation during the first cycle of FOLFOX (5-FU, folinic acid, and oxaliplatin) regimen in the adjuvant setting. Post-resuscitation electrocardiogram revealed ST-elevation in the inferior leads with reciprocal changes. Coronary angiogram revealed no obstructive coronary artery disease. Cardiac workup led to the conclusion of probable fluorouracil-induced vasospasm as the cause of his cardiac arrest. He received implantable cardioverter defibrillator. The decision was made to hold 5-FU. At 3-month follow-up, there was evidence of progressive metastasis. After comprehensive risk-benefit discussions, the decision was made for palliative chemotherapy using 5-FU/leucovorin. A pre-treatment regimen including isosorbide dinitrate, diltiazem, and metoprolol was used. The patient tolerated 5-FU rechallenge without recurrent cardiovascular complication. CONCLUSIONS The cardiotoxicity profile of 5-FU can range from anginal chest pain to sudden cardiac death. When considering 5-FU rechallenge, clinicians should adopt a multidisciplinary approach, favor using prophylactic antianginal therapy, change to bolus dosing, and use continuous telemetry monitoring. Screening patients for dihydropyrimidine dehydrogenase deficiency prior to 5-FU administration may facilitate an individualized strategy for optimal dosing and safety.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: